Form 4: PharmaCyte Biotech Director Robert Weinstein Acquires Stock Options

Director Robert Weinstein acquired 38,009 stock options in PharmaCyte Biotech on April 30, 2024, vesting upon the next annual meeting of stockholders.

Summary

• Robert Weinstein, a director of PharmaCyte Biotech, acquired 38,009 stock options on April 30, 2024.
• The exercise price of these options is $2.12.
• The options vest in full on the date of the Issuer's next annual meeting of stockholders, subject to Mr. Weinstein's continued service.
• The expiration date for these options is April 30, 2034.
• The reporting of this transaction was late due to an inadvertent administrative error.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a standard disclosure of stock option acquisition. The late filing is a minor negative, but the explanation mitigates concern.

Negatives

• The Form 4 filing was late due to an inadvertent administrative error.

Risks

• The vesting of the stock options is contingent upon Mr. Weinstein's continued service with the company.

Future Outlook

The options shall vest in full on the date of the Issuer's next annual meeting of stockholders, subject to the continued service of Mr. Weinstein.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Key Dates

Keywords

stock options, Form 4, director, acquisition, PMCB, PharmaCyte Biotech, Weinstein, insider trading